UK Launches Booster Covid Vaccine Study as B1.617.2 Variant Cases Rise

Thousands of volunteers will receive a booster COVID-19 vaccine in a new clinical trial launching on Wednesday to study the impact of the third jab to protect against the deadly virus, UK Health Secretary Matt Hancock has announced. The Cov-Boost study will trial seven vaccines to provide data on the impact of a third dose on patients’ immune responses, as Britain confirmed 2,967 cases of the B1.617.2 variant first discovered in India up from the 2,323 on Monday.

During a briefing from 10 Downing Street in London, Hancock reiterated UK Prime Minister Boris Johnson’s earlier statement from the House of Commons that there is increasing confidence that the vaccines currently being administered are effective against the B1.617.2 variant, which has been found to be more easily transmissible from person to person. Strong evidence shows the vaccines protect you and your loved ones from serious illness and they also reduce transmission, which is why we’ve introduced additional surge…

Exit mobile version